

CURRICULUM VITAE

Dong-Hoe Koo, M.D., Ph.D.

Title

Associate Professor

Division of Hematology/Oncology, Department of Internal Medicine

Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Office Address

GI Cancer Center, Kangbuk Samsung Hospital,

Sungkyunkwan University School of Medicine

29 Saemunan-ro, Jongno-gu, Seoul 03181, Republic of Korea

Tel: +82-2-2001-8330

Fax: +82-2-2001-8360

E-mail: d.h.koo@samsung.com; d.h.koo@skku.edu

License & Certification

2002 Korean Medical License (#77703)

2007 Diploma, Korean Board of Internal Medicine (#10688)

2013 Korean Board of Hematology-Oncology Specialist (#6-13-443)

Education

2002 M.D., Kyoung-Hee University College of Medicine, Seoul, Korea

2007 MSc, Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea

2014 Ph.D., Postgraduate School, University of Ulsan College of Medicine, Seoul, Korea

(Supervisor: Pf. Yoon-Koo Kang, Asan Medical Center, University of Ulsan College of Medicine)

Postgraduate Training

2002 Internship, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2003-2007 Residency, Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine,
Seoul, Korea

2010 Fellowship in Oncology, Asan Medical Center, University of Ulsan College of Medicine,
Seoul, Korea

2011 Fellowship in Hematology/Oncology, Kangbuk Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, Korea

Career

- 2007-2010 International Doctor (Military service), Korea International Cooperation Agency (KOICA)
Kampong-Cham Referral Hospital, Kampong-Cham, Cambodia
- 2012 Clinical Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2013 Assistant Professor, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2017 Associate Professor, Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Award and Grant

- 2011 Korean Cancer Foundation - Scholarship Grant
- 2011 San Antonio Breast Cancer Symposium (SABCS) - Avon Foundation AACR International Scholar-in-Training Grant
- 2012 Korean Cancer Foundation - Boryung Academic Award
- 2014 Kangbuk Samsung Medical Center - Medical Research Funds for New Investigator
- 2015 Samsung Biomedical Research Institute (SBRI) - Creative Research Initiative Program

Academic Membership

- Member, Korean Medical Association (KMA)
- Member, Korean Association of Internal Medicine (KAIM)
- Member, Korean Cancer Association (KCA)
- Member, Korean Cancer Study Group (KCSG)
- Member, Korean Association of Clinical Oncology (KACO)
- Member, Korean GIST Study Group (KGSG)
- Member, Korean Gastric Cancer Association (KGCA)
- Member, Kangbuk Samsung Hospital Institutional Review Board (KBIRB)
- Member, American Society of Clinical Oncology (ASCO)

Publications

[Corresponding and/or first author]

1. Kwon MY, Cho HN, Koo DH*, Lee YG, Oh S, Lee SS. Initial titration with 200 µg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. Korean J Intern Med. 2017 Jan 24. doi: 10.3904/kjim.2016.044. [Epub] (*Corresponding author)
2. Kim JH, Do IG, Kim K, Sohn JH, Kim HJ, Jeon WK, Lee SR, Son BH, Shin JH, Nam H, Kwon HJ,

- Kim MS, Hong HP, Serrero G, Koo DH*; KBSMC Pancreatobiliary Cancer Team. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma. *Cancer Chemother Pharmacol*. 2016 Nov;78(5):1085-1092. (*Corresponding author)
3. Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, et al. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. *Cancer Res Treat*. 2016 Oct;48(4):1155-1166.
 4. Koo DH, Park I, Ahn JH, Lee DH, et al. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. *Cancer Chemother Pharmacol*. 2016 Feb;77(2):339-47.
 5. Kae YA, Lee MY, Park JS, Kim HJ, Jung TY, Jang BY, Kim YJ, Koo DH*. Ethical Attitudes according to Education and Clinical Experience of Do-Not-Resuscitate (DNR). *Korean J Hosp Palliat Care*. 2015 Sep;18(3):208-218. (*Corresponding author)
 6. Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, et al. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. *Tumour Biol*. 2015 Aug;36(8):5865-71.
 7. Koo DH, Ryu MH, Ryoo BY, Seo J, Lee MY, et al. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12-years of experience at a single institution. *Gastric Cancer*. 2015 Apr;18(2):346-53.
 8. Koo DH, Kim K, Choi CM, Lee DH, Lee JC et al. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. *Cancer Chemother Pharmacol*. 2015 Jan;75(1):197-206.
 9. Koo DH, Ryu MH, Ryoo BY, Beck MY et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. *Cancer Chemother Pharmacol*. 2015 Jan;75(1):173-82
 10. Oh S, Koo DH*, Kwon MJ, Kim K, Suh C, et al. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. *Ann Hematol*. 2014 Aug;93(8):1353-61. (*Co-first author)
 11. Shin DS, Koo DH*, Yoo S, et al: Burnt-out Metastatic Prostate Cancer. *Yeungnam Univ J Med*. 2013 Dec;30(2):116-119. (*Corresponding author)
 12. Koo DH, Oh S, Kim HJ, Jung HL. Long-term Follow-up of Hb Madrid Patient. *Clin Pediatr Hematol Oncol*. 2013 Apr;20(1):55-58.
 13. Jeong EH, Koo DH*, Lee SH, et al. Aggressive Classical Kaposi's Sarcoma Mimicking Malignant Lymphoma. *Pathol Oncol Res*. 2012 Oct;18(4):1067-9. (*Corresponding author)
 14. Koo DH, Park CY, Lee ES, Ro J, Oh SW. Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study. *PLoS One*. 2012;7(6):e39880.

15. Koo DH, Ryu MH, Ryoo BY, Lee SS, Moon JH, et al. Three week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients. *Gastric Cancer*. 2012 Jul;15(3):305-12.
16. Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. *Cancer Chemother Pharmacol*. 2012 Mar;69(3):655-63.
17. Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, et al. Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery. *Oncology*. 2011;80(3-4):208-13.
18. Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A Prognostic Model in Patients who Receive Chemotherapy for Metastatic or Recurrent Gastric Cancer: Validation and Comparison with Previous Models. *Cancer Chemother Pharmacol*. 2011 Oct;68(4):913-21.
19. Koo DH, Yun SC, Hong Y, Ryu M-H, Lee JL, Chang HM, et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. *BMC Cancer*. 2011 May 27;11:205.
20. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, et al. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. *Eur J Surg Oncol*. 2007 Sep;33(7):843-8.
21. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, et al. A Phase II Study of Cetuximab (Erbix) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer. *J Korean Med Sci*. 2007 Sep;22 Suppl:S98-S103.
22. Koo DH, Lee SW, Song SY, Kim SY, Nam SY, Choi SH, et al. Comparison between Surgical and Non-Surgical Treatment of Squamous Cell Carcinoma of Tonsil : Retrospective Analysis of 87 Patients. *Korean J Head Neck Oncol*. 2007;23(1):p.3-8.
23. Koo DH, Oh JS, Choi S-H, Park HG, Lee SS, Kim MK, et al. Monoclonal Proteinuria as a Prognostic Factor for Multiple Myeloma Patients with Intact Immunoglobulin Type. *Korean J Hematol* 2007 Sep; 42(3): 276 - 82.
24. Koo DH, Chang HM, Jung JY, Song JH, Lee JL, Ryu MH, et al. Cutaneous metastasis resembling acute dermatitis in patient with advanced gastric cancer. *Clin Exp Dermatol*. 2007 May;32(3):284-6.
25. Koo DH, Ko OB, Kim S, Lee DH, Kim SW, Suh C. Prospective Randomized Comparative Observations of Infectious Complications with or without Antimicrobial Prophylaxis, during Autologous Stem Cell Transplantation. *Korean J Hematol* 2006 Dec; 41(4): 282 - 8.